The American biotech company Life Biosciences has announced encouraging results from the first human study of a new treatment for glaucoma, an eye condition that often leads to irreversible loss of sight, especially in older adults. The study focuses on a drug, ER-100, which is administered via injection into the eye combined with an antibiotic treatment.
The trial participants in this first phase experienced few side effects, and in two of them, slight improvements in visual field were observed. ER-100 works by reprogramming important genes in the optic nerve cells, potentially rejuvenating and improving the functioning of the cells. This is a novel method aimed at restoring cells rather than simply inhibiting damage.
Glaucoma is a complex disease in which the nerve cells in the eye are damaged and do not recover on their own. There are few effective treatments that can really reverse the process. Therefore, great importance is attached to this rejuvenation technique using epigenetic factors, which alter the genetic material in the cells to counteract aging processes.
With this research, Life Biosciences aims not only to attack glaucoma, but also hopes that this approach can be expanded in the future to treat other degenerative diseases in older adults. The research is still in an early stage, but it offers perspective for a new direction in healthy aging and the preservation of important sensory function.
This development shows that restoring cells and tissues may be a key to preventing age-related diseases and improving quality of life.
Source: Press release
